Viridian Therapeutics Inc. has announced the commencement of an underwritten public offering of shares of its common stock and Series B non-voting convertible preferred stock. All securities in the offering will be sold by Viridian, and the company may also grant underwriters a 30-day option to purchase additional common shares. Each Series B preferred share is convertible into 66.67 shares of common stock, subject to certain ownership limits. Proceeds from the offering are intended to support commercial launch activities for veligrotug and VRDN-003, fund research and development, and provide working capital and general corporate funds. Jefferies, Leerink Partners, Evercore ISI, and Stifel are serving as joint book-running managers, with Wedbush PacGrow acting as co-manager.